Loading organizations...
§ Public · Cambridge, MA, USA
Q32 Bio is a technology company.
Q32 Bio develops novel biologics to restore immune balance in patients with severe autoimmune and inflammatory diseases. Its therapeutic strategy targets powerful regulators of both innate and adaptive immune systems. The company's lead candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) monoclonal antibody, blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling.
Shelia Violette, Ph.D., Dr. David Grayzel, and Michael Broxson co-founded Q32 Bio, leveraging their collective immunology and drug development expertise. Their insight focused on re-regulating adaptive immune function through targeted interventions. Dr. Violette, as Chief Scientific Officer, has guided the scientific approach from inception.
Q32 Bio targets patients with autoimmune and inflammatory diseases like alopecia areata. The company's vision is to advance innovative, targeted therapies that rebalance the immune system, fulfilling unmet medical needs. It aims to improve patient outcomes through pioneering solutions modulating key immune system regulators.
Q32 Bio has raised $106.0M across 2 funding rounds.
Q32 Bio has raised $106.0M in total across 2 funding rounds.
Q32 Bio is a clinical-stage biotechnology company developing biologic therapeutics that target regulators of the innate and adaptive immune systems to restore immune homeostasis in severe autoimmune and inflammatory diseases.[1][2][6] The company serves patients with conditions like alopecia areata, atopic dermatitis, and complement disorders, addressing unmet needs in immune dysregulation through its lead programs: bempikibart (ADX-914), a fully human anti-IL-7Rα antibody blocking IL-7 and TSLP signaling for adaptive immunity, now in Phase 2 for alopecia areata; and ADX-097, a tissue-targeted complement inhibitor in Phase 1 for complement disorders, with the platform under strategic review.[1][4][6][7] Growth momentum includes a 2020 launch with $46M Series A funding, a 2022 collaboration with Horizon Therapeutics on ADX-914, recent CEO transition, and ongoing Phase 2 trials as of Q2 2025, shifting focus to adaptive immunity therapeutics.[1][2][3][7]
Q32 Bio launched in May 2020 from Cambridge, Massachusetts, with a $46M Series A led by Atlas Venture, plus OrbiMed Advisors, Abingworth, and Sanofi Ventures, enabling immediate pipeline advancement.[2] Co-founder and initial Chief Scientific Officer Shelia Violette, Ph.D., brought expertise in immune therapeutics, while Michael Broxson served as CEO, guiding the company from early-stage to clinical progress with programs like ADX-914 (partnered with Horizon in 2022/2023) and ADX-097 (IND-enabling in 2020, Phase 1 ongoing).[1][2][3] A pivotal moment was the Horizon collaboration for ADX-914 in autoimmune diseases, followed by a recent CEO transition where Broxson handed off a robust pipeline, including two advancing clinical programs.[1]
Q32 Bio stands out in immunology biotech through targeted immune modulation:
Q32 Bio rides the wave of precision immunology, targeting IL-7/TSLP and complement pathways amid surging demand for non-steroidal autoimmune therapies, as seen in alopecia areata's limited options and complementopathies' high morbidity.[1][4][7] Timing aligns with post-2020 biotech funding boom enabling quick clinic entry, plus partnerships like Horizon (pre-2023 acquisition by Amgen) accelerating development in a market favoring tissue-selective biologics over broad immunosuppressants.[3] Market forces include genetic validation of IL-7/TSLP in T-cell pathologies and complement's role in ~30+ diseases, positioning Q32 to influence ecosystem shifts toward localized inhibition, potentially reducing side effects and expanding to dermatology, nephrology, and beyond.[4][5]
Q32 Bio's pivot to bempikibart in alopecia areata Phase 2 positions it for near-term catalysts like topline data, while strategic options for its complement platform could yield partnerships or spin-outs amid rising M&A in immunology.[4][5][7] Trends like AI-driven target validation and combo therapies will shape its path, potentially evolving influence through expanded IL-7R applications in broader autoimmunity. As a nimble clinical player born from strong VC backing, Q32 exemplifies biotech's push to reclaim immune control for patients long underserved by one-size-fits-all treatments.[1][2][6]
Q32 Bio has raised $106.0M across 2 funding rounds. Most recently, it raised $60.0M Series B in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2020 | $60M Series B | Acorn Bioventures, OrbiMed | Atlas Venture, Pfizer Venture Investments, Abingworth, Children's Hospital Colorado Center For Innovation, Osage University Partners, Sanofi Ventures, University OF Colorado | Announced |
| May 1, 2020 | $46M Series A | Atlas Venture | Acorn Bioventures, OrbiMed, Pfizer Venture Investments, Abingworth, Children's Hospital Colorado Center For Innovation, Sanofi Ventures, University OF Colorado | Announced |
Q32 Bio has raised $106.0M in total across 2 funding rounds.
Q32 Bio's investors include Acorn Bioventures, OrbiMed, Atlas Venture, Pfizer Venture Investments, Abingworth, Children's Hospital Colorado Center for Innovation, Osage University Partners, Sanofi Ventures, University of Colorado.